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Introduction
Granulomatous meningoencephalomyelitis (GME) is an
idiopathic inflammatory condition of the central nervous system
(CNS) in dogs that was first reported by Braund and colleagues
in 1978. Since that report it has been observed worldwide
(Cordy, 1979; Glastonbury and Frauenfelder 1981; Alley et al.,
1983; Maeda et al., 1993, 1994; Demierre et al., 2001). Early
reports quoted a variable incidence of between 5% and 25% of
all CNS disorders in dogs (Cuddon and Smith-Maxie, 1984);
more recent prevalence information is unavailable. 
Pathology
Histologically, GME lesions occur predominantly within the
white matter of the CNS, characterised by dense aggregates of
inflammatory cells arranged in whorling patterns around blood
vessels. These perivascular cuffs (Figure 1) comprise principally
macrophages along with varying numbers of lymphocytes,
monocytes, plasma cells, and lesser numbers of neutrophils and
multinucleate giant cells (Braund et al., 1978; Cordy, 1979;
Braund, 1985; Kipar et al., 1998). Lymphocytes and
macrophages represent the dominant cell types in the lesions;
however, marked variation is described: some granulomas being
principally lymphoid, some not perivascular, and some with
eccentric development of a granuloma from an existing
perivascular cuff (Alley et al., 1983; Braund, 1985; Kipar et al.,
1998). Typically, lesions are widely distributed within the CNS
but they occur most commonly within the white matter of the
cerebrum, cerebellum, caudal brainstem or cervical spinal cord.
Comparable lesions may also be observed in grey matter and 
there may be lesions involving the vasculature of leptomeninges
Granulomatous meningoencephalomyelitis in dogs: A review 
Emma J. O’Neill
1, Darren Merrett
2 and Boyd Jones
1
1Department of Small Animal Clinical Studies, Faculty of Veterinary Medicine, University College Dublin, Ireland.
2Melbourne Veterinary Referral Centre, Glen Waverley, Victoria, Australia.
Granulomatous meningoencephalomyelitis (GME) is an inflammatory disease of the central
nervous system in dogs that is characterised by focal or disseminated granulomatous lesions
within the brain and/or spinal cord, non-suppurative meningitis and perivascular mononuclear
cuffing. The aetiology of the disease remains unknown, although an immune-mediated cause is
suspected. This article reviewed the typical history, clinical signs and pathology of the condition
along with current opinions on pathogenesis. The potential differential diagnoses for the disease
were discussed along with current treatment options.
Key words
Dog, 
Brain, 
Granulomatous
meningoencephalomyelitis.
Address for correspondence: 
Emma J. O’Neill
Department of Small Animal Clinical Studies, 
Faculty of Veterinary Medicine, University College Dublin, Republic of
Ireland
E-mail: emma.oneill@ucd.ie 
Tel: +353 1 716 6025
Fax: +353 1 716 6023
Irish Veterinary Journal
Volume 58: 86 - 92,2005
FIGURE 1: Sections from
brains of GME cases:
A) Section showing a
characteristic perivascular cuff
lesion around a blood vessel
comprising a predominantly
mononuclear inflammatory cell
infiltrate.Haemotoxylin and
Eosin.Original magnification x40
(top left).
B) Section demonstrating
characteristic ‘whorling’ pattern
of inflammatory cells within the
CNS white matter.Reticulin-
staining.Original magnification
x20 (bottom left).
Abbreviations:
CT: computed tomography, CDV: canine distemper virus, CN:
cranial nerve, CNS: central nervous system, CSF: cerebrospinal
fluid, DTH: delayed-type hypersensitivity, GME:
granulomatous meningoencephalomyelitis, MHC: major
histocompatibility, MRI: magnetic resonance imaging, PCR:
polymerase chain reaction, UMN: upper motor neuron.
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or choroid plexus (Braund, 1985; Sorjonen, 1987a).
Three forms of GME have been described, based primarily on
the presenting clinical signs, namely: focal, disseminated
(multifocal) and ocular (Braund, 1985; Sorjonen, 1987a).
However, in both focal and disseminated forms, the lesions are
usually widely scattered throughout the CNS; in the focal form
there is a coalescence of neighbouring granulomas to give rise
to a space-occupying lesion that is responsible for the clinical
signs of a focal lesion (Braund, 1985; Gearhart et al., 1985;
Sorjonen, 1987b; Thomas and Eger, 1989). Focal lesions are
reported to be more common in the cerebrum and brainstem
(Braund, 1985; Munana and Luttgen, 1998). 
There has been some confusion in the terminology used to
describe GME, particularly in earlier reports where the term
‘reticulosis’ was used to describe the disease (Reviewed: Cuddon
and Smith-Maxie, 1984). Reticulosis refers to “an abnormal
increase in cells derived from, or related to, the monocyte
macrophage” (Cuddon and Smith-Maxie, 1984). Since the
lesions of GME represent an accumulation of macrophages, by
definition GME would represent a subset within the broader
category of reticulosis. The historical description of reticulosis
involved further classification of cases as either inflammatory or
neoplastic reticulosis based on histopathological features such as
mitotic index and cellular pleomorphism (Cuddon and Smith-
Maxie, 1984). The use of this terminology has been largely
superseded; it is generally accepted that GME and inflammatory
reticulosis are terms that have been used to describe the same
condition (Cordy, 1979; Gearhart et al., 1985; Thomas and
Eger, 1989). In addition, as immunohistochemical staining
methods have been applied to some of the archived tissue
sections, it has been shown that some cases previously classified
as neoplastic reticulosis may be more correctly referred to as
CNS lymphosarcoma (Vandevelde et al., 1981). 
Pathogenesis
The pathogenesis of GME is unknown; however, three possible
aetiologies have been considered:
a) An infectious aetiology has been suggested by some authors
(Braund, 1985). However, compelling evidence for any one
infectious agent has not been presented. 
•  Several authors have suggested that, in view of the increased
recognition of GME as the cases of distemper decline with
routine vaccination (Braund, 1985), GME may reflect an
aberrant response to canine distemper virus (CDV), or even
a modified immune response after vaccination. However,
there have only been sporadic reports in the literature
identifying CDV in GME cases, employing either
immunohistochemistry (Vandevelde et al., 1978) or serology
(Sorjonen, 1987b). In addition to their sporadic nature,
these results have not been corroborated by others (Thomas
and Eger, 1989; Kipar et al., 1998); nor have newer
techniques, such as PCR, provided supportive evidence
(Haley et al., 2003). Negri body-like inclusion bodies and
Toxoplasma-like organisms have been reported within lesions;
however, the occurrence of GME within countries known to
be rabies-free (Glastonbury and Frauenfelder, 1981; Alley et
al., 1983) and negative serology results for protozoal
organisms in large studies (Tipold, 1995) would tend to
argue against these aetiologies. 
•  Sutton and Atwell (1982) reported GME in two dogs after
treatment with levamisole (a known immunostimulant);
along with the reported occurrence of inflammatory CNS
lesions following levamisole administration (Vandevelde et
al., 1978), this may suggest a reaction to a previously latent
antigen, possibly of infectious origin.
• A possible aetiological relationship with LaCrosse virus has
been proposed based on similar histopathological findings
(Tatum et al., 1999).
•  Some authors have speculated on the possibility of a
retroviral infection, possibly a vaccine contaminant (Summers
et al., 1995).  
•  A report of GME in two related, co-housed Afghans (Harris
et al., 1988) could suggest an environmental, genetic or
infectious cause.
b) An immune-mediated aetiology has been suggested by
Kipar et al. (1998) and by Wong and Sutton (2002).
Immunohistochemistry demonstrated that inflammatory cells
within GME lesions consisted predominantly of MHC Class
II antigen-positive macrophages and CD3 antigen-positive T
lymphocytes (Kipar et al., 1998). These findings are
suggestive of a T cell-mediated delayed-type hypersensitivity
(DTH) reaction. 
TABLE 1: GME cases: the characteristic history and patient data, with variations 
Classically ... ... but there is marked variability
Age Young adults – middle aged dogs (mean 5 months – 12 years (Sorjonen, 1987a; Thomas and Eger, 1989;
approximately 5 years)  Braund, 2003)
(Munana and Luttgen, 1998; Braund, 2003)
Breed Small breed dog especially toy and terrier ANY breed may get GME, e.g., German shepherd dogs, Great 
breeds and Poodles (Bailey and Higgins, Danes, Pointers, Weimeraners (Braund et al., 1978; Gearhart et 
1986; Braund, 2003) al., 1985; Sorjonen, 1987a)
Sex GME occurs in both sexes; however, there appears to be a higher prevalence in females (Sorjonen, 1987a; Bailey 
and Higgins, 1986; Munana and Luttgen, 1998; Demierre et al., 2001).
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c) Finally, and particularly with large focal GME lesions, a
neoplastic cause has been postulated since such lesions may
have a variable mitotic index and varying degrees of cellular
pleomorphism (Cuddon and Smith-Maxie, 1984). It has
certainly been demonstrated that, on occasion, focal GME
may represent the misdiagnosis of a lesion that is actually
CNS lymphoma or neoplastic histiocytic disease (Vandevelde
et al., 1981).
History and patient data
GME occurs most commonly in young adult small-breed dogs
(Cuddon and Smith-Maxie, 1984; Munana and Luttgen, 1998;
Demierre et al., 2001). However, there is a wide variation in
reported patient data. Table 1 is included to highlight both the
‘classical’ data reported along with variations that have become
apparent as more reports of the condition have been published.
Syndromes and clinical signs 
As is the case with the majority of CNS diseases, the clinical
signs observed in an animal with GME primarily reflect the
location of the inflammatory lesions within the CNS rather than
being specific for the disease itself. Table 2a summarises the
typical clinical signs that are observed with lesions in each of the
main regions of the brain. Table 2b provides a summary of the
clinical signs that have been observed in the GME cases
reported in the literature.
Animals with the disseminated form of the disease have signs
reflecting dysfunction of two or more of the following:
cerebrum, brainstem, cerebellum, spinal cord, meninges, and
optic nerves. This disseminated form accounts for approximately
50% of the GME cases and has generally been accepted to occur
with acute onset (Russo, 1979; Braund, 1985; Munana and
Luttgen, 1998). 
The focal form of GME is characterised by signs attributable to
a single space-occupying lesion. The more commonly reported
signs reflect lesions within the cerebrum and brainstem.
However, clinical signs can reflect a lesion at any location within
the CNS. Focal GME also accounts for approximately 50% of
the presentations and, typically, it has been associated with a
slower onset, e.g., three to six months (Braund, 1985; Munana
and Luttgen, 1998).
Despite this historical perception that the disseminated form has
an acute onset and the focal form has a more chronic
presentation, there is considerable variability (Jones, Merrett
and O’Neill, unpublished data). In addition, this viewpoint that
the disease time course correlates with the focal and
TABLE 2a: Summary of the clinical signs typically associated with lesions in 
specific regions of the brain (adapted from Braund, 2003)
Fore brain: cerebral cortex and thalamus Cerebellum
Seizures
Behavioural changes (loss of training, failure to recognise owner,  Ataxia
aggression, hyperexcitability) Tremor
Altered mental status (apathy, depression, disorientation,  Hypermetria
lethargy, coma) Broad-based stance
Abnormal movements, postures (circling, pacing, wandering,  Menace deficits + normal vision
head-pressing) No weakness
Contralateral deficits: postural reactions, vision, menace response, 
facial sensation
Midbrain Hypothalamus
Upper motor neuron paresis/paralysis all four limbs or contralateral to lesion Normal gait
Postural reaction deficits all four limbs or contralateral to lesion Altered mental status (disorientation, lethargy, coma)
Mental depression/coma Changes in behaviour (aggression/hyperexcitability)
Ipsilateral oculomotor and trochlear deficits Bilateral cranial nerve II deficits at optic chiasm
Hyperventilation  Abnormal movements/postures (tight circling, pacing, 
wandering, head-pressing, trembling)
Abnormal temperature regulation
Abnormal appetite
Endocrine disturbances
Seizures 
Vestibular system (CNS component) Brain stem
Head tilt Ipsilateral hemiparesis/asymmetrical tetraparesis: 
Nystagmus – positional, vertical, horizontal, rotary Upper motor neuron signs
Ataxia  Ipsilateral postural reaction deficits
Postural reaction deficits Cranial nerve abnormalities: V-VII, IX-XII
Altered mental status Altered mental status: depression
Other cranial nerve signs Irregular respiration
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disseminated forms has more recently been challenged by
Demierre et al. (2001) who found that the disease course was
not correlated with the size of lesions but rather with the extent
of mast cell infiltration. 
The ocular form of GME is uncommon and is usually
characterised by sudden onset of blindness due to optic neuritis,
occasionally with uveitis and more rarely with retinal
haemorrhage or detachment (Gelatt, 2000). Typically, the
disease is bilateral but it can be unilateral. Some dogs that
initially present with the ocular form may later progress to
develop other neurological signs (Braund, 1985).
Diagnosis
Routine screening blood tests are often unrewarding for making
a diagnosis of GME (Braund, 2003). In some cases mild to
moderate leukocytosis is observed (Sorjonen, 1987a; Tipold,
1995), although frequently the rise is within the range
encountered with ‘stress’ responses (Sorjonen, 1987a) and
elevations are not seen in the majority of cases (Tipold, 1995).
Whilst CSF analysis is the mainstay of diagnosis (Bailey and
Higgins, 1986), considerable variation in the findings may be
encountered. Table 3 shows the classical features of GME and
variations that may be expected. Figure 2 shows CSF cytology
from a GME case.
Of the few reports of magnetic resonance imaging (MRI) and
computed tomography (CT) scanning of GME lesions, most
have yielded evidence of space-occupying lesions that cannot be
definitively differentiated from neoplastic lesions (Dzyban and
Tidwell, 1996; Speciale et al., 1992). In one report of 12
histopathologically confirmed GME cases that underwent CT
scanning, the only statistically significant differentiating feature
of GME cases was the hyperdense appearance of the lesion prior
to contrast enhancement (Gibbons et al., 1999). Variable MRI
findings have been reported (Lonbetti and Pearson, 1995).
Unsurprisingly, there are no reports of detection of the
(microscopic) disseminated lesions.
Brain biopsy is required to make a definitive antemortem
diagnosis of GME and, in particular, to differentiate focal GME
lesions from neoplastic disease (Summers et al., 1995).
Differential diagnoses
As discussed above, the observed clinical signs most typically
relate to the location of the lesion rather than to its nature
(Braund, 2003). Hence, the list of differential diagnoses to be
considered is often large. The clinical detection of a diffuse CNS
disease is most suggestive of infectious, inflammatory or
neoplastic disease. Signs of a focal CNS lesion can occur with
any space-occupying lesion (e.g., neoplasm, inflammatory
granuloma, cyst, or infarct). Furthermore, there are numerous
potential causes of optic neuritis. Hence, the clinical findings are
far from specific.
CSF analysis demonstrating a mononuclear pleocytosis may be
consistent with:
TABLE 2b: The frequency of clinical signs described in
151 GME cases reported in the literature 
It should be noted that these numbers represent an
approximation only. The major limitation is that papers vary in
the details given and in their classification of the clinical signs. 
Some listed the specific clinical signs, others listed the affected
regions of the brain. Here the signs are listed as they were
given in the papers (from Braund et al., 1978; Glastonbury
and Frauenfelder, 1981; Alley et al., 1983; Gearhart et al.,
1985; Bailey and Higgins, 1986; Sorjonen, 1987b; Thomas
and Eger, 1989; Munana and Luttgen, 1998; Harris et al.,
1988; Speciale et al., 1992; Tipold, 1995; Lonbetti and
Pearson, 1995; Dzyban and Tidwell, 1996).
Clinical signs Number of cases
Head tilt 6
Circling 7
Nystagmus 1
Seizures 11
Behavioural changes 7
Depression 10
Ataxia 22
Gait abnormalities 16
Proprioceptive deficits 16
Postural reaction deficits 5
Dysmetria 11
Exaggerated reflexes 8
Tremors 6
Hyperaesthesia 15
Pelvic/thoracic limb paresis 17
Cranial nerve deficits 17
Blindness/optic neuritis 15
Facial paralysis 1
Febrile 19
Cervical pain 37
Forebrain 25
Brainstem 15
Vestibular 13
Cortical 11
Cerebellar/vestibular 10
Myelopathies 7
Spinal cord 4
Cerebellar 3
FIGURE 2: Cerebrospinal fluid cytology demonstrating mononuclear cell
pleocytosis in a case of GME.Original magnification x40.
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a. Viral encephalitides (e.g., canine distemper)
In order to rule out canine distemper, one must perform
canine distemper virus antibody titres or canine distemper
virus PCR on CSF samples. 
b. Protozoal encephalomyelitides (e.g., toxoplasmosis,
neosporosis)
These diseases represent major differential diagnoses
(Braund, 2003) and in order to differentiate them from
GME one should carefully assess the patient for extra-CNS
disease. In addition, serum titres for antibodies or
CSF/serum PCR for organism can be evaluated.
c.  Fungal encephalomyelitides (e.g., cryptococcosis) 
Fungal CNS infection typically gives rise to a greater
eosinophilic component in the CSF and fungal elements may
be identified in the CSF (Braund, 2003).
d. Necrotising meningoencepalitides
There are several sporadic reports of clinically acute and
severe, multifocal, diffuse CNS diseases; typically characterised
by non-suppurative necrotising meningoencephalitis. Such
‘syndromes’ are recognised as clinical entities affecting
particular breeds: for example, pyogranulomatous
meningoencephalitis of Pointers (Braund, 1980) and Pug dog
encephalitis (Cordy and Holliday, 1989), which is recognised
also in Maltese terriers (Stalis et al., 1995), Pekingese (Cantile
et al., 2001) and Yorkshire terriers (Jull et al., 1997). These
separate disease entities are typically associated with a
particular constellation of clinical signs and would be
suspected in dogs of the relevant breed demonstrating
compatible clinical signs and changes in the CSF.
e. Neoplasia
Some cases of CNS lymphoid or histiocytic neoplasia are
misdiagnosed as “GME” (Vandevelde et al., 1981; Cuddon
and Smith-Maxie, 1984; Suzuki et al., 2003). This is not
surprising since the CT/MRI appearance can be identical
and, on occasion, particularly with meningiomas (Gibbons et
al., 1999), there can be significant overlap between findings
on CSF analysis (Tippold, 1995).
Treatment
The traditional mainstay of therapy has been corticosteroids, in
particular prednisolone used at immunosuppressive doses (2
mg/kg/day) tapered with response over the following months to
achieve the lowest dose possible that controls signs (Platt, 2002).
It is uncommon for corticosteroid therapy to be terminated.
Patients often have a good initial response, but as the dose is
tapered, or with time, signs often recur and subsequently prove
difficult to control with an increased dose of prednisolone.
Sometimes, reducing the dose of prednisolone that had resulted in
control of clinical signs can result in a severe recurrence of signs
and it has not always been possible to regain control (D. Merrett,
unpublished data).
Of late there seems to have been a noticeable increase in the
number of alternative agents that have been used to manage this
condition. Unfortunately, each treatment typically involves small
numbers of cases, making it impossible to draw significant
conclusions on the efficacy or advantage of each individual agent.
Some of the agents that have been used for GME are listed below:
•  Azathioprine has been administered in combination with
corticosteroids to allow the dose of the steroid to be reduced
to avoid undesirable side effects of prolonged steroid
TABLE 3: CSF in granulomatous meningoencephalomyelitis: the classical findings, variations and the responses to treatment with
corticosteroids
Classically ... ... but there is marked variability
Leucocyte count 50 – 900 (Braund, 2003) 0 – 11,840
(cells/µL) Occasional cases (~10%) may have normal leucocyte counts
(Thomas and Eger, 1989).
Cytology Mononuclear pleocytosis usually  Occasional cases (~10%) may have up to 50-60% neutrophils 
consisting of lymphocytes  (Bailey and Higgins, 1986; Munana and Luttgen, 1998).
(60 to 90%), monocytes (10 to 20%)  Some cases with relatively fewer lymphocytes than monocytes
and variable numbers of large  (Bailey and Higgins, 1986).
macrophages with lacy cytoplasm 
(Braund, 2003)
Protein (g/L) 40 to 400 (Braund, 2003) 9 to 1,848 (Munana and Luttgen, 1998)
Occasional cases (~5 to 10%) may have normal protein 
concentrations (Tipold, 1995).
Corticosteroid response In one study, eight dogs were treated with corticosteroids prior to CSF analysis and the mean WCC 
and protein content of the CSF of these dogs did not differ significantly from non-treated cases 
(Bailey and Higgins, 1986).
In another study of 16 CSF samples analysed, the only two samples that were normal were in dogs 
previously treated with corticosteroids (Demierre et al., 2001). 
However, it should be noted that the great variability of dose, the nature and the timing of prior therapy make it 
impossible to draw conclusions other than to say that prior treatment with corticosteroids can possibly have “some” effect 
on CSF analysis.
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administration (Jones, Merrett and O’Neill, unpublished
data).
•  Cytosine arabinoside – an antineoplastic agent that acts on
dividing cells by blocking pyrimidine synthesis and causes
premature termination of the DNA chain. This drug has
been used to treat lymphoma and myeloproliferative diseases
and recent reports demonstrated success in controlling GME
signs (Cuddon et al., 2002; Nuhsbaum et al., 2002).
•  Procarbazine – an antineoplastic agent that damages DNA
and affects protein and RNA synthesis. This agent has also
been recently reported to have a positive effect on control of
GME lesions (Cuddon et al., 2002).
•  Cyclosporine, a potent suppressor of T cell function, has also
been used with some benefit in a small number of cases
(Adamo and O’Brien, 2004).
Radiation therapy, either focally directed or whole brain, has
been described in a few papers. In one study, seven of 42 dogs
received radiation therapy, of which six had focal forebrain signs
and one dog had multifocal signs (Munana and Luttgen, 1998).
The dog with multifocal signs did not respond and was
euthanased shortly after completion of the course of radiation
therapy. The six irradiated dogs had significantly longer survival
times than the other dogs with focal forebrain signs that did not
receive radiation therapy (treated with corticosteroids): the
median survival time of irradiated dogs was more than 404 days
(longest surviving patient more than 1,215 days), whereas the
median survival time of dogs not irradiated was 41 days (longest
surviving patient approximately 800 days).
Prognosis
GME has a poor prognosis. Most studies offer the
generalisations that dogs with multifocal disease typically have a
short survival (e.g., up to six weeks after diagnosis) and dogs
with focal disease usually have a longer survival (e.g., three to
six months). There are single case reports of dogs responding
for longer periods. However, large prospective studies
monitoring clinical responses to the newer treatment modalities
are lacking and are greatly needed to allow an accurate
prognosis to be given. It is the authors’ perception that the
current literature provides a more negatively biased impression
of the disease. Whilst the disease does carry a guarded
prognosis, some individuals will respond to treatment for a
considerable period of time.
Conclusions
•  The presentation of GME can be extremely variable. Patients
can present with acute or chronic, focal or multifocal CNS
signs, suggesting pathology at many levels of the CNS.
•  GME is a difficult disease to definitively diagnose since there
are many differentials for the presenting signs and the finding
of a mononuclear pleocytosis in CSF.
•  Corticosteroids currently remain the mainstay of therapy but,
because of the less-than-ideal survival time, there is active
interest in a number of other agents.
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